Newsroom

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update. “We are off to a strong start in 2026, building on the clinical and scientific progress achieved last year,” said Arun Swaminathan, Ph.D., Chief Executive O...

DALLAS--(BUSINESS WIRE)--NeuWire Medical, a medical device company advancing the development of a targeted plasticity therapy platform for individuals living with chronic ischemic stroke, today announced the appointment of Ramin Mousavi as Executive Chairman of the Board. His arrival marks an important step in the company’s next phase of growth as NeuWire Medical prepares to advance its clinical, regulatory, and financing strategy. Ramin joins NeuWire Medical following his role as President, Ch...

CAPE TOWN, South Africa--(BUSINESS WIRE)--Impulse Biomedical, a Cape Town-based healthcare company focused on advancing asthma and allergy care through developing more accessible and patient-focused products, is excited to announce its acceptance into the Maryland Global Gateway Soft Landing Program, which marks a major milestone in its global expansion plans. The company, focused on developing and commercializing its patented ZiBiPen® reloadable autoinjector and patented Easy Squeezy® asthma a...

MONTRÉAL--(BUSINESS WIRE)--Foodtastic, chef de file dans la restauration, a annoncé aujourd’hui avoir obtenu les droits de franchisage de la bannière Dunkin’ au Canada en vue d’ouvrir des centaines d’établissements partout au pays. En vertu du nouvel accord, Foodtastic disposera de droits exclusifs pour développer la marque Dunkin’ à l’échelle nationale. Cette expansion renforce la relation entre Foodtastic et Inspire Brands et ajoute à son portefeuille canadien un concept de café et de beignes...

ATLANTA--(BUSINESS WIRE)--OnPay, a top-rated payroll and HR provider for small- and mid-sized businesses, today announced the launch of its integration with Betterment at Work, a leading provider of modern, scalable 401(k) plans. The new partnership helps employers manage payroll and retirement benefits more easily and accurately through a connected experience. Together, OnPay and Betterment at Work are expanding the options available to small businesses that want their payroll and 401(k) to wo...

MIAMI--(BUSINESS WIRE)--Real Expands in Kansas City...

TORONTO & MONTREAL--(BUSINESS WIRE)--Equisoft and Continuum launch an AI-powered Equisoft/connect integration with automated meeting notes, task sync, and intelligent CRM search....

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in New York City: HCW 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026, 4:00-4:30 pm ET RBC Global Healthcare Conference: Wednesday, May 20, 2026, 9:30-9:55 am ET A live webcast of the fire...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for COYA 302, a proprietary investigational biologic combination therapy with a dual mechanism of action, for the treatment of amyotrophic late...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced preliminary positive data from the ongoing open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a recent analysis of subjects who el...